5432452026-07-202026-07-205432452026-07-205432452026-07-20

ChangeInManagementDomain1

5432452026-07-202026-07-20

ChangeInManagementDomain1

5432452026-07-20

ChangeInManagementDomain2

5432452026-07-202026-07-20

ChangeInManagementDomain2

xbrli:pure

GLAND

GLAND Pharma Limited

543245

NOTLISTED

INE068V01023

true

Listed Entity (self)

false

2026-07-18

17:00:00

2026-07-20

Re-appointment

Director

Non - Executive Independent Director

Not Applicable

Mr.

Udo Jahannes Vetter

2026-07-21

false

Appointment

Director

Non - Executive Independent Director

Not Applicable

Mr.

William Robert Keller

2026-06-15

Mr. William Robert Keller, aged 78, is currently an Independent Director of Wuxi Biologics, a global Contract Research, Development and Manufacturing Organization (CRDMO) in Biologics, listed on Hongkong Stock Exchange. He is also an Independent Director on Hua Medicine, a Company listed on Hongkong Stock Exchange. During August, 2020 to August, 2025 Mr. William Keller was a Director of Cathay Biotech Inc, which is listed on Shanghai Stock exchange. He was the Chairman of Coland Pharmaceutical Co. Ltd (earlier listed on Taiwan Stock Exchange) for ten years till November, 2020. Earlier, from December, 2009 to May, 2015; he was an Independent Director on the Board of Alexion Pharmaceuticals Inc., a Nasdaq listed entity. For seven years, till December, 2014 Mr. William Keller was also an Independent Director of Taigen Biopharmaceutical Holding Limited, a Taiwan Stock Exchange listed company. Mr. William Keller has more than 40 years of experience in managing operations in South America and Asia, particularly in pharmaceutical and biotechnology sectors. Mr. Keller spent almost three decades in different management positions with Roche in South America and Asia. From 1990 to 1994, he served as the Managing Director of Roche Hong Kong with regional responsibilities, and subsequently from 1994 to 2003, he was the General Manager for Roche China Holding, and Shanghai Roche Pharmaceutical Ltd., where he established and built up the Roche business in China. In 2003, Mr. Keller founded Keller Pharma Consultancy, a pharmaceutical consulting firm focusing on market entry strategies for foreign biotech companies into the Chinese market and supporting biopharma start-up companies in Shanghai. During June, 1997 to December, 2013 Mr. Keller served as the Vice Chairman of the Shanghai Association of Enterprises with Foreign Investment, advising and supporting foreign invested companies as a business advisor. From March, 2003 to June, 2014; Mr. Keller was appointed as Deputy General Manager of Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co. Ltd, focusing on pharmaceutical and biotechnological industry development. From March, 2003 to December, 2013, he served as a senior consultant of the Shanghai Foreign Investment Development Board, providing advice regarding foreign investment development. From May, 2007 to April, 2010, Mr. Keller served as the Chairman of HBM Biomed China Partners Ltd., overseeing investments in biotechnology companies. Mr. Keller holds a Bachelor of Science degree from the School of Economics and Business Administration in Zurich, Switzerland, in July, 1972.

Not Applicable

true

false